Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZ-001 + Valganciclovir in Glioblastoma
NCT06102525Phase 2Recruiting
- Sponsor
- Rznomics
- Start
- Oct 2024
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of RZ-001 in glioblastoma (GBM), sponsored by Rznomics. Started Oct 2024; status: recruiting.
02
Drugs
RZ-001
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06102525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102525.